Selective aromatase inhibition for patients with androgen-independent prostate carcinoma: A phase II study of letrozole

Cancer

Volumn 95, Issue 9, 2002, Pages 1864-1868

  Smith, Matthew R ^a   Kaufman, Donald ^a   George, Daniel ^b   Oh, William K ^b   Kazanis, Maryanne ^a,b   Manola, Judith ^b   Kantoff, Philip W ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Androgen independent; Aromatase; Letrozole; Prostatatic neoplasms

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; LETROZOLE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; LUMBAR DISK HERNIA; MALE; MUSCLE CRAMP; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ENZYME INHIBITORS; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TRIAZOLES;

EID: 0036840477     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10844     Document Type: Article

References (23)

1. Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: Brake pedal or accelerator? Am J Pathol. 2001;159:13-16.
2. Kruithof-Dekker IG, Tetu B, Janssen PJ, Van der Kwast TH. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. J Urol. 1996;156:1194-1197.
3. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990;173:534-540.
4. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to anti-androgens. J Steroid Biochem Mol Biol. 1992;41:665-669.
5. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-1398.
6. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A Phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998;52:257-260.
7. Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in "hormone-refractory" prostate cancer. Ann Oncol. 2000;11:177-81.
8. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595-3603.
9. Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H. Tamoxifen in refractory metastatic carcinoma of the prostate. Cancer Treat Rep. 1980;64:813-818.
10. Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer. 1982;49:1367-1372.
11. Spremulli E, DeSimone P, Durant J. A Phase II study Nolvadex: Tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am J Clin Oncol. 1982;5:149-153.
12. Torti FM, Lum BL, Lo R, Freiha F, Shortliffe L. Tamoxifen in advanced prostatic carcinoma. A dose escalation study. Cancer. 1984;54:739-743.
13. Horton J, Rosenbaum C, Cummings FJ. Tamoxifen in advanced prostate cancer: An ECOG pilot study. Prostate. 1988;12:173-177.
14. Smith MR, Kantoff PW, Oh W, et al. Phase II trial of the antiestrogen toremifene for androgen-independent prostate cancer. Prostate J. 1999;1:185-189.
15. Stein S, Zoltick B, Peacock T, et al. Phase II trial of toremifene in androgen-independent prostate cancer: A Penn Cancer Clinical Trials Group trial. Am J Clin Oncol. 2001;24:283-285.
16. Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer. 2001;92:2095-2101.
17. Davies JH, Dowsett M, Jacobs S, Coombes RC, Hedley A, Shearer RJ. Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. Br J Cancer. 1992;66:139-142.
18. Dearnaley DP, Shearer RJ, Gallagher C, et al. A Phase I/II study with rogletimide in patients with hormone resistant prostatic cancer. Ann Oncol. 1994;5(Suppl 8):179.
19. Buzdar A, Howell A. Advances in aromatase inhibition: Clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620-2635.
20. Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol. 1996;35(Suppl 5):15-18.
21. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
22. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555-3561.
23. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948-955.